Background and Objectives: Cervical cancer is a leading cause of cancer death in female populations. It is a virally induced carcinoma resulting from sexually transmitted high risk Human Papillomavirus infections (e.g. HPV-16, HPV-18). Previous studies have shown associations between IL-17A levels in cancer micro-environments and metastasis of tumor cells. In Africa, chemotherapy (CT) is the standard first-line treatment for cervical cancer and the prognosis remains poor for metastatic and recurrent cases. The impact of CT as a treatment option is still unclear. We investigated the prognostic relevance of IL-17A profiles in Cervical cancer patients (CP) patients treated with cisplatin in combination with 5-fluouracil (5FU) for three cycles. Methods: The study included 57 CP and 59 women with no history of malignancy as healthy controls (HC). IL-17A plasma levels were evaluated by ELISA. For each CP, three blood samples were collected at three-week intervals before initiation of the chemotherapy protocol. Results: Before chemotherapy CP showed higher serum levels of IL-17A compared to HCs (p = 0.035). No relation was detected between age and IL-17A levels. We observed a significant increase in serum IL-17A during treatment of the CP group (p < 0.05). Depending on chemotherapy’s efficacy, CP were divided into 1) non responders, 2) partial responders and 3) good responders. Non-responders patients showed significantly higher serum levels of IL-17A during the follow-up compared to partial and good responder groups both following the first CT cycle (p < 0.05) and the second CT cycle (p < 0.03). Conclusion: Our results suggest that high serum levels of IL-17A are associated with poor responses to classical chemotherapy. However, considering these results to design CC biomarkers, we need further investigations particularly about the relevant prognostic indicator following chemotherapy.
References
[1]
Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. https://doi.org/10.3322/caac.21387
[2]
Schiffman, M.H. and Brinton, L.A. (1995) The Epidemiology of Cervical Carcinogenesis. Cancer, 76, 1888-1901.
https://doi.org/10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H
[3]
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D., Forman, D. and Bray, F. (2013) Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11.
[4]
Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J. and Schreiber, R.D. (2001) IFNgamma and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. Nature, 410, 1107-1111.
https://doi.org/10.1038/35074122
Marzo, A.L., Kinnear, B.F., Lake, R.A., Frelinger, J.J., Collins, E.J., Robinson, B.W.S. and Scott, B. (2000) Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity. The Journal of Immunology, 165, 6047-6055. https://doi.org/10.4049/jimmunol.165.11.6047
[7]
Street, S.E., Cretney, E. and Smyth, M.J. (2001) Perforin and Interferon-Gamma Activities Independently Control Tumor Initiation, Growth, and Metastasis. Blood, 97, 192-197. https://doi.org/10.1182/blood.V97.1.192
[8]
Street, S.E., Trapani, J.A., MacGregor, D. and Smyth, M.J. (2002) Suppression of Lymphoma and Epithelial Malignancies Effected by IFN Gamma. Journal of Experimental Medicine, 196, 129-134. https://doi.org/10.1084/jem.20020063
[9]
Kolls, J.K. and Linden, A. (2004) Interleukin-17 Family Members and Inflammation. Immunity, 21, 467-476.
https://doi.org/10.1016/j.immuni.2004.08.018
[10]
Zou, W. and Restifo, N.P. (2010) TH17 Cells in Tumour Immunity and Immunotherapy. Nature Reviews Immunology, 10, 248-256.
https://doi.org/10.1038/nri2742
[11]
Souza, J.M., Matias, B.F., Rodrigues, C.M., Murta, E.F. and Michelin, M.A. (2013) IL-17 and IL-22 Serum Cytokine Levels in Patients with Squamous Intraepithelial Lesion and Invasive Cervical Carcinoma. European Journal of Gynaecological Oncology, 34, 466-468.
[12]
Cua, D.J. and Tato, C.M. (2010) Innate IL-17-Producing Cells: The Sentinels of the Immune System. Nature Reviews Immunology, 10, 479-489.
https://doi.org/10.1038/nri2800
[13]
Pelletier, M., Maggi, L., Micheletti, A., Lazzeri, E., Tamassia, N., Costantini, C., Cosmi, L., Lunardi, C., Annunziato, F., Romagnani, S. and Cassatella, M.A. (2010) Evidence for a Cross-Talk between Human Neutrophils and Th17 Cells. Blood, 115, 335-343. https://doi.org/10.1182/blood-2009-04-216085
[14]
Marchetti, C., De Felice, F., Di Pinto, A., Romito, A., Musella, A., Palaia, I., Monti, M., Tombolin, V., Muzii, L. and Benedetti Panici, P. (2018) Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer. Cancer Research and Treatment, 50, 768-776.
https://doi.org/10.4143/crt.2017.141
[15]
Mallmann, P. (2016) A Change of Paradigm in the Treatment of Cervical Cancer. Oncology Research and Treatment, 39, 500. https://doi.org/10.1159/000448967
[16]
Waggoner, S.E. (2003) Cervical Cancer. The Lancet, 361, 2217-2225.
https://doi.org/10.1016/S0140-6736(03)13778-6
[17]
Ndiaye, R., Dem, A., Mbaye, P.M., Guèye, P.M., Diop, G., Diop, P.A. and Faye, O. (2014) étude du codon 72 du gène p53 dans la prédisposition au cancer du col de l’utérus au Sénégal. Bulletin du Cancer, 101, 789-794.
[18]
Dem, A., Dieng, M.M., Traore, B., Gaye, M., Diop, M. and Touré, P. (2008) Les carcinomes épidermoides du col utérin à l’Institut du cancer de Dakar. Cahiers d’études et de recherches francophones/Santé, 18, 31-33.
https://doi.org/10.1684/san.2008.0094
[19]
Zhu, X., Mulcahy, L.A., Mohammed, R.A., Lee, A.H., Franks, H.A., Kilpatrick, L., Yilmazer, A., Paish, E.C., Ellis, I.O., Patel, P.M. and Jackson, A.M. (2008) IL-17 Expression by Breast-Cancer-Associated Macrophages: IL-17 Promotes Invasiveness of Breast Cancer Cell Lines. Breast Cancer Research, 10, R95.
https://doi.org/10.1186/bcr2195
[20]
Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T. and Fujiyama, Y. (2003) Increased Expression of Interleukin 17 in Inflammatory Bowel Disease. Gut, 52, 65-70. https://doi.org/10.1136/gut.52.1.65
[21]
Li, Q., Chen, J., Liu, Y., Zhao, X., Tan, B., Ai, J., Zhang, Z., Song, J. and Shan, B. (2013) Prevalence of Th17 and Treg Cells in Gastric Cancer Patients and Its Correlation with Clinical Parameters. Oncology Reports, 30, 1215-1222.
https://doi.org/10.3892/or.2013.2570
[22]
Zhang, J.P., Yan, J., Xu, J., Pang, X.H., Chen, M.S., Li, L., Wu, C., Li, S.P. and Zheng, L. (2009) Increased Intratumoral IL-17-Producing Cells Correlate with Poor Survival in Hepatocellular Carcinoma Patients. Journal of Hepatology, 50, 980-989.
https://doi.org/10.1016/j.jhep.2008.12.033
[23]
Kato, T., Furumoto, H., Ogura, T., Onishi, Y., Irahara, M., Yamano, S., Kamada, M. and Aono, T. (2001) Expression of IL-17 mRNA in Ovarian Cancer. Biochemical and Biophysical Research Communications, 282, 735-738.
https://doi.org/10.1006/bbrc.2001.4618
[24]
Lyon, D.E., McCain, N.L., Walter, J. and Schubert, C. (2008) Cytokine Comparisons between Women with Breast Cancer and Women with a Negative Breast Biopsy. Nursing Research, 57, 51-58. https://doi.org/10.1097/01.NNR.0000280655.58266.6c
[25]
Bettelli, E., Korn, T., Oukka, M. and Kuchroo, V.K. (2008) Induction and Effector Functions of TH17 Cells. Nature, 453, 1051-1057.
https://doi.org/10.1038/nature07036
[26]
Nam, J.S., Terabe, M., Kang, M.J., Chae, H., Voong, N., Yang, Y.A., Laurence, A., Michalowska, A., Mamura, M., Lonning, S., Berzofsky, J.A. and Wakefield, L.M. (2008) Transforming Growth Factor Beta Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17. Cancer Research, 68, 3915-3923. https://doi.org/10.1158/0008-5472.CAN-08-0206
[27]
Kryczek, I., Wei, S., Zou, L., Altuwaijri, S., Szeliga, W., Kolls, J., Chang, A. and Zou, W. (2007) Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment. The Journal of Immunology, 178, 6730-6733. https://doi.org/10.4049/jimmunol.178.11.6730
[28]
Becht, E., Giraldo, N.A., Dieu-Nosjean, M.C., Sautes-Fridman, C. and Fridman, W.H. (2016) Cancer Immune Contexture and Immunotherapy. Current Opinion in Immunology, 39, 7-13. https://doi.org/10.1016/j.coi.2015.11.009
[29]
Numasaki, M., Fukushi, J., Ono, M., Narula, S.K., Zavodny, P.J., Kudo, T., Robbins, P.D., Tahara, H. and Lotze, M.T. (2003) Interleukin-17 Promotes Angiogenesis and Tumor Growth. Blood, 101, 2620-2627.
https://doi.org/10.1182/blood-2002-05-1461
